European Commission Approves Faslodex-Ibrance Combo for Advanced Breast Cancer

European Commission Approves Faslodex-Ibrance Combo for Advanced Breast Cancer
The European Commission (EC) has extended the approval of AstraZeneca‘s breast cancer therapy Faslodex (fulvestrant) to be used in combination with Ibrance (palbociclib) for advanced breast cancers. The combination can now be used to treat women with hormone receptor-positive (HR+), HER2-negative, locally advanced or metastatic breast cancer who have received prior hormone therapy. “For many years fulvestrant has been used

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *